ISSN: 1859 - 2872
Effictiveness and safety of rivaroxaban in comparison with acenocoumarol in patients with non-valvular atrial fibrillation at Thai Nguyen Central Hospital
Main Article Content
Keywords
Abstract
Objective: To compare effectiveness and safety of rivaroxaban with acenocoumarol in patients with non-valvular atrial fibrillation. Subject and method: Prospective, descriptive, longitudinal fllow-up study and follow up study. 153 patients with non-valvular atrial fibrillation at Thai Nguyen Central Hospital, including 91 patients in the acenocoumarol group (Group I) and 62 patients in the rivaroxaban group (Group II) were recruited. Result: CHA2DS2-VASc score of group I was 4.69 ± 1.30, group II was 4.71 ± 1.09, the HAS-BLED Score of group I was 1.96 ± 0.63, group II was 1.81 ± 0.65. Rivaroxaban reduced the risk of thromboembolic by 45.5% as compared with acenocoumarol, with 95% CI [0.19-1.53], not statistically significant with p>0.05. Rivaroxaban reduced the risk of bleeding by 74.5% on comparison with acenocoumarol with 95% CI [0.07-0.87], statistically significant with p<0.05. Conclusion: In patients with non-valvular atrial fibrillation, rivaroxaban was noninferior to acenocoumarol in prevention of stroke or systemic embolism, rivaroxaban had a better safety profile.
Article Details
References
2. Blumer V, Rivera M, Corbalan R et al (2021) Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. Am Heart J 236: 4-12.
3. Cam AJ, Kirchohof P, Lip GYH et al (2010) Guidelines for the management of atrial fibrillation: the Task Force for the management of atrial fibrillation of the european society of cardiology (ESC). Europace 12(10): 1360-1420.
4. Coleman CI, Antz M, Bowrin K et al (2016) Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin 32(12): 2047-2053.
5. Chugh SS, Havmoeller R, Nayrayanan K et al (2014) Worldwide epidemiology of atrial fibrillation: A Global burden of disease 2010 study. Circulation. 129(8): 837-847.
6. Kim YH, Shim J, Tsai CT et al (2018) XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J Arrhythm 34(4): 418-427.
7. Hindricks G, Potpara T, Dagres N et al (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal 42(5): 373-498.
Article Sidebar
